Pharmafile Logo

nab-paclitaxel

- PMLiVE

Celgene’s president and COO to retire

Scott Smith set to succeed Dr Jacqualyn Fouse from 1 April

National Institute for Health and Care Excellence NICE logo

Amicus gets NICE green light for Fabry drug

Oral therapy alternative Galafold approved for routine NHS use

- PMLiVE

Lighting the way

How the UK’s Accelerated Access Review aims to guide medical innovations to their destination

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s Ibrance over high cost

Draft guidance on breast cancer therapy calls for more evidence of its benefits

- PMLiVE

NICE to bring HTA processes to mobile health apps

But its new evidence briefings will stop short of issuing guidance on their use

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

Institute reverses its initial verdict on Janssen's oncology treatment

Celgene building

Celgene pays $300m upfront for immunology start-up Delinia

Broadens its pipeline with autoimmune disease candidate due to start trials in 2018

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links